140 related articles for article (PubMed ID: 38135213)
41. Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments.
Turner AJ; Sammon C; Latimer N; Adamson B; Beal B; Subbiah V; Abrams KR; Ray J
Pharmacoeconomics; 2024 Feb; 42(2):165-176. PubMed ID: 37891433
[TBL] [Abstract][Full Text] [Related]
42. Framework for considering the role of data bases in technology assessment.
Moses LE
Int J Technol Assess Health Care; 1990; 6(2):183-93. PubMed ID: 2144266
[TBL] [Abstract][Full Text] [Related]
43. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
44. Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology.
Hunink MG; Krestin GP
Radiology; 2002 Mar; 222(3):604-14. PubMed ID: 11867773
[TBL] [Abstract][Full Text] [Related]
45. Information Patients Can Provide Will Strengthen the Real-World Evidence That Matters to Them.
Nowell WB
Clin Pharmacol Ther; 2019 Jul; 106(1):49-51. PubMed ID: 31112287
[No Abstract] [Full Text] [Related]
46. HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT: REAL-WORLD EVIDENCE FOR PUBLIC HEALTHCARE SUSTAINABILITY.
Guerra-Júnior AA; Pires de Lemos LL; Godman B; Bennie M; Osorio-de-Castro CGS; Alvares J; Heaney A; Vassallo CA; Wettermark B; Benguria-Arrate G; Gutierrez-Ibarluzea I; Santos VCC; Petramale CA; Acurcio FA
Int J Technol Assess Health Care; 2017 Jan; 33(2):279-287. PubMed ID: 28641588
[TBL] [Abstract][Full Text] [Related]
47. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
Polisena J; Jayaraman G
Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
[TBL] [Abstract][Full Text] [Related]
48. Assessment of diagnostic technologies. Methodology for unbiased estimation from samples of selectively verified patients.
Greenes RA; Begg CB
Invest Radiol; 1985 Oct; 20(7):751-6. PubMed ID: 3835974
[TBL] [Abstract][Full Text] [Related]
49. Some considerations on target estimands for health technology assessment.
Remiro-Azócar A
Stat Med; 2022 Dec; 41(28):5592-5596. PubMed ID: 36385477
[No Abstract] [Full Text] [Related]
50. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
51. Is this the real life? Is this just fantasy?
Grainger D
Int J Technol Assess Health Care; 2014 Jul; 30(3):239-40. PubMed ID: 25077981
[No Abstract] [Full Text] [Related]
52. [Quality of health care, accreditation, and health technology assessment in Croatia: role of agency for quality and accreditation in health].
Mittermayer R; Huić M; Mestrović J
Acta Med Croatica; 2010 Dec; 64(5):425-34. PubMed ID: 21692267
[TBL] [Abstract][Full Text] [Related]
53. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
54. Prostheses for primary total hip replacement. A critical appraisal of the literature.
Cowley DE
Int J Technol Assess Health Care; 1995; 11(4):770-8. PubMed ID: 8567209
[TBL] [Abstract][Full Text] [Related]
55. Data acquisition for assessment of medical technology: methods other than technical trials.
Moses LE
Int J Technol Assess Health Care; 1986; 2(1):27-38. PubMed ID: 10276248
[No Abstract] [Full Text] [Related]
56. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
Timbie JW; Kim AY; Concannon TW
Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
[TBL] [Abstract][Full Text] [Related]
57. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10.
Simpson A; Ramagopalan SV
J Comp Eff Res; 2023 Jan; 12(1):e220194. PubMed ID: 36453665
[TBL] [Abstract][Full Text] [Related]
58. Guidance from key organisations on exploring, confirming and interpreting subgroup effects of medical treatments: a scoping review.
Wijn SRW; Rovers MM; Le LH; Belias M; Hoogland J; IntHout J; Debray T; Reitsma JB
BMJ Open; 2019 Aug; 9(8):e028751. PubMed ID: 31446407
[TBL] [Abstract][Full Text] [Related]
59. The "ethics of evidence" and randomized controlled trials.
Truog RD; Arnold JH
J Clin Ethics; 1992; 3(1):65-7. PubMed ID: 11643058
[No Abstract] [Full Text] [Related]
60. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
